Lyell Immunopharma, Inc. (NASDAQ:LYEL) Stock Has Average Target Price of $40.86

Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) have been given a consensus rating of “Moderate Buy” by the nine research firms that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $40.86.

A number of equities research analysts have commented on the company. Royal Bank Of Canada set a $34.00 target price on Lyell Immunopharma in a research report on Friday, August 14th. Weiss Ratings restated a “sell (d-)” rating on shares of Lyell Immunopharma in a report on Friday, July 17th. Needham & Company LLC reaffirmed a “buy” rating and issued a $44.00 target price on shares of Lyell Immunopharma in a research report on Friday, September 11th. HC Wainwright reiterated a “buy” rating on shares of Lyell Immunopharma in a research report on Friday, September 11th. Finally, Citizens Jmp reiterated a “market outperform” rating and set a $34.00 price target on shares of Lyell Immunopharma in a research report on Monday, June 15th.

Institutional Trading of Lyell Immunopharma

Several institutional investors have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC lifted its stake in Lyell Immunopharma by 194.8% during the first quarter. Renaissance Technologies LLC now owns 116,411 shares of the company’s stock worth $2,335,000 after purchasing an additional 76,921 shares in the last quarter. Opaleye Management Inc. grew its stake in shares of Lyell Immunopharma by 334.9% in the second quarter. Opaleye Management Inc. now owns 344,025 shares of the company’s stock valued at $4,834,000 after buying an additional 264,928 shares in the last quarter. MWG Caph Ltd acquired a new stake in shares of Lyell Immunopharma in the fourth quarter valued at $31,030,000. venBio Partners LLC purchased a new stake in shares of Lyell Immunopharma in the 2nd quarter valued at $4,744,643. Finally, Dimensional Fund Advisors LP purchased a new stake in shares of Lyell Immunopharma in the 1st quarter valued at $959,000. Institutional investors and hedge funds own 66.05% of the company’s stock.

Lyell Immunopharma Price Performance

NASDAQ:LYEL opened at $9.26 on Friday. The company’s 50-day moving average is $12.97 and its two-hundred day moving average is $15.84. Lyell Immunopharma has a 1-year low of $9.21 and a 1-year high of $45.00. The firm has a market capitalization of $226.87 million, a price-to-earnings ratio of -0.72 and a beta of -0.03.

Lyell Immunopharma (NASDAQ:LYEL) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($1.92) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.94) by $0.02. Lyell Immunopharma had a negative net margin of 920,285.25% and a negative return on equity of 91.62%. The business had revenue of $0.00 million during the quarter, compared to the consensus estimate of $0.00 million. As a group, equities analysts anticipate that Lyell Immunopharma will post -7.16 earnings per share for the current fiscal year.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc is a clinical-stage biotechnology company focused on developing engineered T-cell therapies for cancer, with an emphasis on solid tumors. The company seeks to address limitations of existing cell therapies, including T-cell exhaustion, limited persistence and reduced activity within the tumor microenvironment.

Lyell uses cell-engineering and genomic technologies to develop investigational chimeric antigen receptor (CAR) T-cell and T-cell receptor (TCR) therapies.